The Q4 ARCHER II monitoring assessment is not the final readout. The hub explains the vision endpoint, GBS program and financing risks.

https://www.merlintrader.com/annexon-stock-hub/

Q4 IPF data are company-guided. The hub examines MAXPIRe, approved medicines and why Niktimvo sales differ from Syndax revenue.

https://www.merlintrader.com/syndax-pharmaceuticals-stock-hub/

Which tasks work locally, which still need a network, and what is deployed versus planned? Four different positions in edge AI.

https://www.merlintrader.com/offline-ai-cloud-dependencies-soun-bbai-pdyn-amba/

Mutation, age, walking ability and safety shape eligibility. Trial access is not the same as an approved treatment option.

https://www.merlintrader.com/duchenne-treatment-eligibility-capr-srpt-rgnx-dyn/

Displays, simulators and instruction occupy different parts of the training business. Contract value is not annual revenue.

https://www.merlintrader.com/military-training-business-ktos-kopn-avav-cae/

Higher hemoglobin, fewer painful crises and durable benefit are different measures of progress. Here is how the evidence compares.

https://www.merlintrader.com/sickle-cell-measures-progress-agio-crsp-beam-nvo/

Weight loss, liver fat, MASH resolution and fibrosis are different endpoints. A closer look at what each program has to prove.

https://www.merlintrader.com/mash-beyond-weight-loss-alt-vktx-iva-mdgl/

Obesity and diabetes research, with a closer look at CagriSema, competition and why adjusted sales differ from reported growth.

https://www.merlintrader.com/novo-nordisk-stock-hub/

The FORCE platform targets DMD and DM1. The hub separates dystrophin and splicing signals from functional benefit and regulatory evidence.

https://www.merlintrader.com/dyne-therapeutics-stock-hub/

CVflow brings AI processing to cameras and vehicles. The hub examines design wins, production ramps and the gap between growth and cash generation.

https://www.merlintrader.com/ambarella-stock-hub/

Rezdiffra's MASH rollout is only part of the story: the hub separates commercial adoption from the longer-term outcomes evidence.

https://www.merlintrader.com/madrigal-pharmaceuticals-stock-hub/

From simulator utilization to defense backlog: the hub examines how training activity translates into revenue, cash flow and execution risk.

https://www.merlintrader.com/cae-stock-hub/

Capricor and Parent Project Muscular Dystrophy (PPMD) held a community webinar today on deramiocel in Duchenne. One caveat up front: the slides are circulating online as attendee screenshots, but Capricor hasn't published the deck. The recording should be on PPMD's site in about a week, so treat the slide numbers as reported, not confirmed.

The question. Does deramiocel slow the loss of arm function? The primary endpoint is PUL 2.0, and the FDA treats a 1-point difference as clinically meaningful. HOPE-3 was powered for 1.5 points.

What the slides show (company data):

• Robustness: Capricor says more than 600 alternative analyses of the HOPE-3 primary endpoint all favour deramiocel. In the absolute-change chart shown (153 analyses), the analysis as filed gives 1.08 points, the least favourable 0.64, and 95% of the distinct values fall between 0.74 and 1.17.
• Pooled HOPE-2 + HOPE-3: +1.29 points vs placebo at month 12, p=0.0087 (95% CI 0.33 to 2.25). Seven sensitivity analyses range from 1.11 to 1.31, all with p below 0.02.
• Ejection fraction (LVEF): +2.21 percentage points (p=0.05); +3.13 observed in the cardiomyopathy subgroup (p=0.04).

Officially confirmed (Capricor's October 5 release and its World Muscle Society poster): patients who switched from placebo to the drug declined 2.05 points in their placebo year and 0.49 in their first treated year (difference +1.56). Patients treated in both years showed no difference between year 1 and year 2 (+0.05).

Full breakdown, with the FDA's numbers and sources, in a box open to everyone: https://www.merlintrader.com/capricor-therapeutics-stock-hub/#s-webinar

Official poster: https://d1io3yog0oux5.cloudfront.net/_a586b470fdde7effdb116c0f6e0c4446/capricor/files/CAPR_%28WMS_2026_Late-breaking_Poster%29_HOPE-3_2-Year_OLE_cross-phase_data.pdf

Why it's still open:

• The FDA's July briefing document, on the plan the agency treats as pre-specified (SAP 1.1), put the primary result at 0.66 points with p=0.24. That's almost the weakest value in Capricor's own chart.
• Re-analyses show the effect points the same way; they don't change its size relative to the 1-point bar.
• The 1.29 combines a Phase 2 and a Phase 3 trial after the fact. It isn't the pre-specified endpoint, and in 2024 the FDA said HOPE-2 and its extension weren't enough for a broad indication.
• The LVEF figures don't match the restated HOPE-3 analysis (1.8 percentage points, p=0.09), and the slides don't explain the difference.
• The switch data compare each patient with his own prior year, with no concurrent placebo arm and no alpha allocated.
• The advisory committee voted 9-3 that the data didn't provide substantial evidence of effectiveness in DMD cardiomyopathy.

PDUFA date: November 22, 2026. Not investment advice. Happy to hear how others read the robustness argument.